|
Mutation Information
|
Mutation Site
|
M204I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204I+rt.A181S |
|
Relevant Drug
|
adefovir (ADV);lamivudine (LAM);tenofovir (TDF);clevudine (L-FMAU);emtricitabine (FTC) |
Literature Information
|
PubMed PMID
|
17713159
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2007 |
|
Journal
|
Antiviral therapy |
|
Title
|
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. |
|
Author
|
Karatayli E,Karayalçin S,Karaaslan H,Kayhan H,Türkyilmaz AR,Sahin F,Yurdaydin C,Bozdayi AM |
|
Evidence
|
The complete genome comprising the A181S+M2041 pattern was cloned into an expression vector and its in vitro susceptibility to 3TC, ADV, tenofovir (PMPA), clevudine (L-FMAU) and emtricitabine (FTC) were determined in transiently transfected Huh7 cells
|
|
|
HBV Mutation Detail Information